ArticleInternational journal of clinical oncology2018
Multi-panel assay of serum autoantibodies in colorectal cancer.
Article in International journal of clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Prognostic and diagnostic significance of serum p53 antibody levels in patients with surgically treated pancreatic cancer.Oncology letters · 2026Article
- Prognostic significance of six autoantibodies in esophageal squamous cell carcinoma: A prospective multi-institutional study.Annals of gastroenterological surgery · 2025Article
- Autoantibody repertoire profiling in tissue and blood identifies colorectal cancer-specific biomarkers.Cancer science · 2024Article
- Prognostic and diagnostic significance of preoperative Jumonji domain‑containing 6 antibodies in colorectal cancer.Oncology letters · 2023Article
- Altered immunity to microbiota, B cell activation and depleted γδ/resident memory T cells in colorectal cancer.Cancer immunology, immunotherapy : CII · 2022Article
- Six autoantibodies as potential differential biomarkers of hepatocellular carcinoma vs. liver cirrhosis and chronic hepatitis: A prospective multi-institutional study.Oncology letters · 2022Article
- Article
- Presence of serum RalA and serum p53 autoantibodies in 1833 patients with various types of cancers.International journal of clinical oncology · 2022Article
- Systematic pan-cancer analysis identifies RALA as a tumor targeting immune therapeutic and prognostic marker.Frontiers in immunology · 2022Article
- Article
- Multipanel assay of 17 tumor-associated antibodies for serological detection of stage 0/I breast cancer.Cancer science · 2021Article
- The Roadmap of Colorectal Cancer Screening.Cancers · 2021Review
- Review
- Clinical value of tumor-associated antigens and autoantibody panel combination detection in the early diagnostic of lung cancer.Cancer biomarkers : section A of Disease markers · 2021Article
- IgM and IgA augmented autoantibody signatures improve early-stage detection of colorectal cancer prior to nodal and distant spread.Clinical & translational immunology · 2021Article
- Possible predictive significance of serum RalA autoantibodies on relapse-free survival in patients with colorectal cancer.Molecular and clinical oncology · 2021Article
- Article
- Prevalence of autoantibodies against Ras-like GTPases, RalA, in patients with gastric cancer.Molecular and clinical oncology · 2020Article
- Blood-derived molecular signatures as biomarker panels for the early detection of colorectal cancer.Molecular biology reports · 2020Review
- Clinical value of seven autoantibodies combined detection in the diagnosis of lung cancer.Journal of clinical laboratory analysis · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundAlthough serum p53 autoantibodies (s-p53-Abs) are induced even in the early stages of colorectal cancer, their positive rate is only approximately 20%. Therefore, we assessed the possibility of using other serum autoantibodies to increase the positive rates for detecting colorectal cancer.
methodsAutoantibodies against 17 tumor antigens (p53, RalA, HSP70, Galectin1, KM-HN-1, NY-ESO-1, p90, Sui1, HSP40, CyclinB1, HCC-22-5, c-myc, PrxVI, VEGF, HCA25a, p62, and Annexin II) were evaluated in 279 patients with colorectal cancer and 74 healthy controls. Cutoff values were fixed at mean + 3 standard deviations of serum titers in healthy controls.
resultsAutoantibodies with the highest positive rates were p53 (20%), RalA (14%), HSP70 (12%), and Galectin1 (11%). Combination assays using multiple autoantibodies increased the positive rates based on the number of autoantibodies used. Positive rates of 56, 62, 66, 71, and 73% were obtained with 6, 9, 11, 14, and 17 antibodies, respectively, for the overall disease. Moreover, these autoantibodies showed relatively high positive rates even during stage 0/I disease (55 and 70% with 6 and 17 antibodies, respectively).
conclusionThe measurement of set of 17 autoantibodies allowed autoantibody profiling in patients with colorectal cancer. The combination assay of six tumor antigens (p53, RalA, HSP70, Galectin1, KM-HN-1, and NY-ESO-1) achieved a positive rate of 56%. Such high positive rates will be helpful for detecting colorectal cancer regardless of tumor stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.